Citigroup Raises Madrigal Price Target to $760 From $725, Keeps Buy
Citigroup raised its price target on Madrigal Pharmaceuticals to $760 a share from $725 and kept its Buy rating, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Citigroup raised its price target on Madrigal Pharmaceuticals (MDGL) to $760 a share from $725 and maintained its Buy rating. Dow Jones Newswires reported the move, citing ratings actions compiled by Benzinga.
The report does not give the analyst's reasoning behind the change.
why it matters
A price-target revision reflects one analyst's valuation view rather than a new development at the company, so its market impact is usually limited. For MDGL holders, it is one data point on sentiment toward the stock.
tags
instruments
sources
- Madrigal Pharmaceuticals Price Target Raised to $760.00/Share From $725.00 by Citigroup — Dow Jones Newswires, 3 November 2026 at 19:31 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗